Pharmamarketeer

Invokana Gets FDA’s Priority Review for CKD in T2D Indication

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease (ESRD) and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).

Medhc-fases-banner
Advertentie(s)